CINtec PLUS Cytology test more effective than HC2 HPV test in identifying women with precancerous lesions

Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, today announced the publication of further results from the Primary ASC-US LSIL Marker Study (PALMS) in this month's issue of Cancer Cytopathology. The PALMS study, which enrolled more than 27,000 women from five European countries, was designed to evaluate the diagnostic performance of the CINtec® PLUS Cytology test in detecting pre-cancerous cervical disease compared to HPV testing and more traditional screening methods like Pap cytology.

In this latest publication based on the PALMS study results, the CINtec PLUS Cytology test was compared to pooled, high-risk HPV DNA testing as a triage or follow-up screening method for mildly abnormal Pap cytology results. The study confirmed that the CINtec PLUS Cytology test had significantly higher specificity and was more effective overall than the HC2 HPV test in identifying women with precancerous lesions. These results suggest that if implemented as a triage test in a cytology-based screening program, the CINtec PLUS Cytology test may lead to a reduction in the overtreatment of women screened for cervical disease.

"These latest results of PALMS confirm data from previous studies which have shown that incorporating the CINtec PLUS Cytology test in cervical cancer screening programs can provide real benefit to both clinicians and their patients," says Dr. Christine Bergeron, Laboratoire Cerba, Cergy Pontoise, France, PALMS study investigator and publication author. "As a triage test for abnormal cervical cancer screening results, the CINtec PLUS Cytology test could be very useful to differentiate women who will benefit most from immediate referral to colposcopy and diagnostic follow-up, from those women who can be followed up with less invasive methods."

More than 500,000 new cases of cervical cancer are diagnosed each year worldwide and the average five-year survival rate of patients is only around 50%. HPV infections are common and cause virtually all cervical cancer; however, only those women with persistent HPV infections and who have developed high-grade precancerous cervical disease should be treated. The CINtec PLUS Cytology test was developed to help identify the subgroup of women with underlying transforming HPV infections that may lead to cancer and distinguish them from those with mostly transient infections.

"The results observed in PALMS are consistent with those demonstrated in many other published studies" said Tim Himes, Lifecycle Leader, CINtec and HPV-mediated Disease. "As countries begin to move towards primary screening with HPV, the need for an improved triage test will increase dramatically. We are therefore pleased to see that the CINtec PLUS Cytology test consistently demonstrates strong performance when used in the triage setting. By overcoming the known issues with Pap cytology, the test is well positioned to provide immediate benefit to women, doctors and screening programs globally."


Ventana Medical Systems, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
A faster, safer and more affordable technology to produce personalized cancer therapies